hATTR-PN

As a columnist for Amyloidosis News Today since October 2020, I’ve written about various topics, all related to my experience caring for a spouse…

One year after a single dose of Intellia Therapeutics’ experimental gene-editing therapy NTLA-2001, blood levels of the disease-driving transthyretin (TTR) protein dropped by…

The U.S. Food and Drug Administration (FDA) has given orphan drug designation to AT-02, Attralus’ investigational candidate for the treatment of transthyretin amyloidosis…

Diflunisal is used off-label to treat familial amyloid polyneuropathy (FAP), but it may be as safe and effective as tafamidis free acid, which is…

Adults with familial amyloid polyneuropathy (FAP) living in Canada may soon be able to receive Amvuttra (vutisiran) at little or no cost through…

The Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K. has approved the injection therapy eplontersen — under the brand name Wainzua —…

About a month ago, my father-in-law came down with what seemed like a cold. But his condition gradually worsened, which sent him to the hospital.

My late husband, Aubrey, was diagnosed with hereditary ATTR amyloidosis in 2013 and passed away on May 22, 2022. Those nine years were spent…

Applying a fluorescent green tracer called AMDX-9101 during a routine eye exam may enable the detection of the toxic transthyretin protein deposits that cause symptoms…

Gly103Arg, a mutation in the TTR gene that has been exclusively reported in Chinese people, is associated with a familial amyloid polyneuropathy-like profile marked…